WeVote
Log In

Bill

Bill

HB 1470

An Act amending the act of June 13, 1967 (P.L.31, No.21), known as the Human Services Code, in public assistance, providing for subscription model for GLP-1 agonists.

2025-2026 Regular Session Introduced by Johanny Cepeda-Freytiz and 15 co-sponsors

Pennsylvania bill establishes subscription model for GLP-1 weight-loss and diabetes medications through public assistance programs to improve access for low-income residents.

Referred to Human Services
0
WeVote Research Nonpartisan
Bill Summary · HB 1470

Legislative bill overview

HB 1470 would amend Pennsylvania's Human Services Code to establish a subscription model through which the state could provide GLP-1 agonist medications (such as Ozempic, Wegovy, and Mounjaro—drugs used for weight loss and diabetes management) to eligible public assistance recipients. The bill restructures how these medications are accessed and funded within the state's assistance programs rather than relying on traditional per-prescription dispensing.

Why is this important

GLP-1 agonists are among the most expensive medications on the market, with costs exceeding $1,000 per month without insurance, making them inaccessible to many low-income Pennsylvanians despite clinical evidence of effectiveness for weight management and diabetes control. A subscription model could reduce per-unit costs through bulk purchasing and predictable demand, potentially expanding access to these medications for disadvantaged populations while managing state budget exposure. This reflects a broader policy trend nationally around addressing obesity and metabolic disease in underserved communities.

Potential points of contention

  • Cost and fiscal impact: Whether subscription models actually reduce state spending long-term, or if expanded access increases overall expenditures beyond current budget projections
  • Medical appropriateness and equity: Debates over whether weight-loss medications should be prioritized in public assistance programs versus other health interventions, and whether this appropriately targets those with greatest medical need
  • Pharmaceutical industry dynamics: Concerns that state subscription programs could influence drug pricing, manufacturer relationships, or create conflicts with existing pharmacy benefit managers and insurance arrangements

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.